Another Study Finds Marijuana An Effective Treatment Against Migraines
Marijuana Industry NewsMedical Marijuana September 26, 2020 MJ Shareholders 0
Nearly 1 in 4 U.S. households and about a billion people worldwide suffer from migraines, according to the Migraine Research Foundation. But new data shows 30% of U.S. migraine patients have turned to cannabis for pain relief with 83% of them reporting improved symptoms.
Researchers used data collected through Healint’s Migraine Buddy, a global migraine tracking app that records the frequency and intensity of attacks, as well as sleep and dietary triggers. Patients used a variety of cannabis delivery methods, including smoking, vaping, edibles, and tinctures. None were shown to be more effective than others.
“Cannabis is becoming a prominent treatment option for chronic pain patients, especially for migraineurs,” said Healint CEO and co-founder Francois Cadiou.
“Research about the benefits of cannabis use among migraine patients is slowly emerging, but more must be done to properly inform individuals about the use and dosage of medical marijuana to treat migraines.”
Several past studies back up these newest claims. Researchers behind a recent study published in the journal Brain Sciences found that sustained cannabis consumption led to decreased migraine frequency over time. “These findings indicate that medical cannabis results in long-term reduction of migraine frequency in >60% of treated patients and is associated with less disability and lower antimigraine medication intake.” [Read more at LA Weekly]
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
No comments so far.
Be first to leave comment below.